Louisa Hoes
Cancers will increasingly meet the definition of ‘rare’ in terms of the molecular profiles that make each tumor unique. The more research we can do into this, the better we will be able to offer patients personalized treatment in the future. Whole Genome Sequencing and studies like DRUP are making an important contribution to this.
Back to newsMore news
GLOW Study Ends – But WGS Remains Valuable for Glioblastoma Patients
As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …
Podcast HealthRewired: where data and treatment come together
“What we ultimately want is to be able to provide every cancer patient with a personalized treatment recommendation.” Prof. Dr. Miriam …
Patients can benefit from whole genome sequencing for immunotherapy
Immunotherapy is an effective treatment for many people with cancer. The number of abnormalities in the DNA of the tumor in …
The number of WGS samples Hartwig Medical Foundation has is quite unique in the research field and is rapidly growing. It amounted to 3.500 samples when we started and it’s already over 5.000 now.